UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 312

Sortiert nach

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

The lancet oncology, 2020-06, Vol.21 (6), p.808-820

2020

Volltextzugriff (PDF)

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Annals of oncology, 2018-06, Vol.29 (6), p.1402-1408

2018

Volltextzugriff (PDF)

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group

Annals of oncology, 2008-08, Vol.19 (8), p.1477-1484

2008

Volltextzugriff (PDF)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Annals of oncology, 2020-03, Vol.31 (3), p.334-351

2020

Volltextzugriff (PDF)

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

Annals of oncology, 2018-05, Vol.29 (5), p.1220-1226

2018

Volltextzugriff (PDF)

Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Annals of oncology, 2018-10, Vol.29, p.viii718-viii719

2018

Volltextzugriff (PDF)

Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors

Annals of oncology, 2014-11, Vol.25 (11), p.2272-2277

2014

Volltextzugriff (PDF)

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)

Annals of oncology, 2015-10, Vol.26 (10), p.2097-2101

2015

Volltextzugriff (PDF)

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

Annals of oncology, 2008-12, Vol.19 (12), p.2079-2083

2008

Volltextzugriff (PDF)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

British journal of cancer, 2012-03, Vol.106 (6), p.1039-1044

2012

Volltextzugriff (PDF)

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

British journal of cancer, 2013-10, Vol.109 (9), p.2309-2315

2013

Volltextzugriff (PDF)

Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study

Annals of oncology, 2018-11, Vol.29, p.ix47-ix47

2018

Volltextzugriff (PDF)

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

The New England journal of medicine, 2018-07, Vol.379 (1), p.54-63

2018

Volltextzugriff (PDF)

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study

ESMO open, 2021-06, Vol.6 (3), p.100119, Article 100119

2021

Volltextzugriff (PDF)

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer

British journal of cancer, 2006-04, Vol.94 (7), p.959-963

2006

Volltextzugriff (PDF)

Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

Annals of oncology, 2019-07, Vol.30, p.iv135-iv136

2019

Volltextzugriff (PDF)

Prognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)

Annals of oncology, 2018-10, Vol.29, p.viii262-viii262

2018

Volltextzugriff (PDF)

Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)

Annals of oncology, 2018-11, Vol.29, p.ix61-ix61

2018

Volltextzugriff (PDF)

Efficacy and safety of regorafenib after progression on sorafenib in Korean patients with advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2018-11, Vol.29, p.ix56-ix56

2018

Volltextzugriff (PDF)

Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX

ESMO open, 2022-06, Vol.7 (3), p.100484-100484, Article 100484

2022

Volltextzugriff (PDF)

Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)

Annals of oncology, 2018-10, Vol.29, p.viii247-viii248

2018

Volltextzugriff (PDF)

Evaluation of genetic alterations in biliary tract cancer using targeted exome sequencing

Annals of oncology, 2018-10, Vol.29, p.viii257-viii258

2018

Volltextzugriff (PDF)

Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis

Annals of oncology, 2018-10, Vol.29, p.viii245-viii245

2018

Volltextzugriff (PDF)

Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2018-10, Vol.29, p.viii207-viii207

2018

Volltextzugriff (PDF)

Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2018-11, Vol.29, p.ix46-ix46

2018

Volltextzugriff (PDF)

1 – 25 von 312

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(284)
Mit Volltextzugriff
(283)

Publikationsform

Artikel
(293)
Tagungsberichte
(19)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy

Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer

Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

Prognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)

Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)

Efficacy and safety of regorafenib after progression on sorafenib in Korean patients with advanced hepatocellular carcinoma (HCC)

Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX

Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)

Evaluation of genetic alterations in biliary tract cancer using targeted exome sequencing

Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis

Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)

Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Suchergebnisse filtern